Literature DB >> 25311202

Validation of an ambulatory capacity measure in Parkinson disease: a construct derived from the Unified Parkinson's Disease Rating Scale.

Sotirios A Parashos1, Jordan Elm2, James T Boyd3, Kelvin L Chou4, Lin Dai2, Zoltan Mari5, John C Morgan6, Lewis Sudarsky7, Catherine L Wielinski1.   

Abstract

BACKGROUND: A construct calculated as the sum of items 13-15, 29, 30 of the Unified Parkinson's Disease Rating Scale (UPDRS) has been used as an "Ambulatory Capacity Measure" (ACM) in Parkinson disease (PD). Its construct validity has never been examined. A similar construct, consisting of the mean value of the same UPDRS items has been used under the acronym PIGD as a measure of postural instability and gait disorder in PD.
OBJECTIVE: To examine the construct validity of the ACM and PIGD in PD.
METHODS: We analyzed data in an existing database of 340 PD patients, Hoehn and Yahr stages (HYS) 1-5 who participated in a study of falls. Number of falls (NOF) was recorded over 4 weeks, and UPDRS (mental, ADL, and motor subscales), HYS, Activities Based Confidence Scale (ABC), Freezing of Gait Questionnaire (FOG), Five Times Sit-to-Stand (FTSS), Timed Up-and Go (TUG), Gait Velocity (GV), and Berg Balance Scale (BBS) evaluations were performed. Internal consistency was assessed by Cronbach's alpha. Construct validity was assessed through correlations of the ACM and PIGD to these measures and to their summed-ranks. A coefficient of determination was calculated through linear regression.
RESULTS: Mean age was 71.4, mean age at diagnosis 61.4 years; 46% were women; mean UPDRS subscale scores were: Mental 3.7; ADL 15.7; motor: 27.1; mean ACM was 6.51, and mean PIGD 1.30. Cronbach's alpha was 0.78 for both ACM and PIGD. Spearman correlation coefficients between the ACM/PIGD and ABC, FOG, TUG, GV and BBS were 0.69, 0.72, 0.67, 0.58, and 0.70 respectively. Correlation between the ACM/PIGD and summed-ranks of HYS, NOF, ABC, FOG, FTSS, TUG, GV and BBS was high (Spearman r = 0.823, p < 0.0001); 68% of the variability in the summed-ranks was explained by ACM/PIGD.
CONCLUSION: The ACM and the PIGD are valid global measures and accurately reflect the combined effects of the various components of ambulatory capacity in PD patients with HY stages 1-4.

Entities:  

Keywords:  Idiopathic Parkinson disease; PIGD; ambulation; ambulatory capacity; balance; falls; scales

Mesh:

Year:  2015        PMID: 25311202      PMCID: PMC4478048          DOI: 10.3233/JPD-140405

Source DB:  PubMed          Journal:  J Parkinsons Dis        ISSN: 1877-7171            Impact factor:   5.568


  28 in total

1.  Quality criteria were proposed for measurement properties of health status questionnaires.

Authors:  Caroline B Terwee; Sandra D M Bot; Michael R de Boer; Daniëlle A W M van der Windt; Dirk L Knol; Joost Dekker; Lex M Bouter; Henrica C W de Vet
Journal:  J Clin Epidemiol       Date:  2006-08-24       Impact factor: 6.437

2.  Risk of falling in Parkinson's disease at the Hoehn-Yahr stage III.

Authors:  Hiroshi Kataoka; Noriyuki Tanaka; M Eng; Keigo Saeki; Takao Kiriyama; Nobuyuki Eura; Masanori Ikeda; Tesseki Izumi; Takanori Kitauti; Yoshiko Furiya; Kazuma Sugie; Yoshito Ikada; Satoshi Ueno
Journal:  Eur Neurol       Date:  2011-11-01       Impact factor: 1.710

3.  Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times.

Authors:  Ying Jiao Zhao; Hwee Lin Wee; Yiong-Huak Chan; Soo Hoon Seah; Wing Lok Au; Puay Ngoh Lau; Emmanuel Camara Pica; Shu Chuen Li; Nan Luo; Louis C S Tan
Journal:  Mov Disord       Date:  2010-04-30       Impact factor: 10.338

4.  Recurrent falls and mortality in Parkinson's disease: a prospective two-year follow-up study.

Authors:  M Matinolli; J T Korpelainen; K A Sotaniemi; V V Myllylä; R Korpelainen
Journal:  Acta Neurol Scand       Date:  2011-03       Impact factor: 3.209

5.  The Activities-specific Balance Confidence (ABC) Scale.

Authors:  L E Powell; A M Myers
Journal:  J Gerontol A Biol Sci Med Sci       Date:  1995-01       Impact factor: 6.053

6.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

7.  Five times sit-to-stand test performance in Parkinson's disease.

Authors:  Ryan P Duncan; Abigail L Leddy; Gammon M Earhart
Journal:  Arch Phys Med Rehabil       Date:  2011-09       Impact factor: 3.966

8.  Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1.

Authors:  Jordan J Elm
Journal:  Mov Disord       Date:  2012-10       Impact factor: 10.338

9.  Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial.

Authors:  Andrew Siderowf; Michael McDermott; Karl Kieburtz; Karen Blindauer; Sandra Plumb; Ira Shoulson
Journal:  Mov Disord       Date:  2002-07       Impact factor: 10.338

10.  The instrumented timed up and go test: potential outcome measure for disease modifying therapies in Parkinson's disease.

Authors:  Cris Zampieri; Arash Salarian; Patricia Carlson-Kuhta; Kamiar Aminian; John G Nutt; Fay B Horak
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-09-02       Impact factor: 10.154

View more
  6 in total

1.  Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort.

Authors:  Kelvin L Chou; Jordan J Elm; Catherine L Wielinski; David K Simon; Michael J Aminoff; Chadwick W Christine; Grace S Liang; Robert A Hauser; Lewis Sudarsky; Chizoba C Umeh; Tiffini Voss; Jorge Juncos; John Y Fang; James T Boyd; Ivan Bodis-Wollner; Zoltan Mari; John C Morgan; Anne-Marie Wills; Stephen L Lee; Sotirios A Parashos
Journal:  J Neurol Sci       Date:  2017-04-11       Impact factor: 3.181

2.  Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.

Authors: 
Journal:  Lancet Neurol       Date:  2015-06-23       Impact factor: 44.182

3.  Measures of balance and falls risk prediction in people with Parkinson's disease: a systematic review of psychometric properties.

Authors:  Stanley J Winser; Priya Kannan; Umar Muhhamad Bello; Susan L Whitney
Journal:  Clin Rehabil       Date:  2019-10-01       Impact factor: 3.477

4.  Vitamin B12 measurements across neurodegenerative disorders.

Authors:  Nijee S Luthra; Ariane H Marcus; Nancy K Hills; Chadwick W Christine
Journal:  J Clin Mov Disord       Date:  2020-03-12

5.  Relationship of Cerebrospinal Fluid Vitamin B12 Status Markers With Parkinson's Disease Progression.

Authors:  Chadwick W Christine; Peggy Auinger; Nasrin Saleh; Miao Tian; Teodoro Bottiglieri; Erland Arning; Nam K Tran; Per Magne Ueland; Ralph Green
Journal:  Mov Disord       Date:  2020-05-14       Impact factor: 10.338

6.  What is Functional Mobility Applied to Parkinson's Disease?

Authors:  Raquel Bouça-Machado; Walter Maetzler; Joaquim J Ferreira
Journal:  J Parkinsons Dis       Date:  2018       Impact factor: 5.568

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.